Currently, NovoCure Ltd [NVCR] is trading at $16.02, down -1.17%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NVCR shares have lost -8.98% over the last week, with a monthly amount drifted -8.09%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
NovoCure Ltd [NASDAQ: NVCR] stock has seen the most recent analyst activity on July 08, 2025, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $30. Previously, Evercore ISI upgraded its rating to Outperform on December 02, 2024, and elevated its price target to $30. On October 16, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $30 on the stock. H.C. Wainwright downgraded its rating to a Neutral and reduced its price target to $25 on August 28, 2023. Piper Sandler upgraded its rating to Overweight for this stock on August 08, 2023, but kept the price target unchanged to $45. In a note dated August 04, 2023, SVB Securities initiated an Outperform rating and provided a target price of $51 on this stock.
This stock has fluctuated between a low of $14.17 and a high of $34.13 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $71.5 within the next 12 months. NovoCure Ltd [NASDAQ: NVCR] shares were valued at $16.02 at the most recent close of the market. An investor can expect a potential return of 346.32% based on the average NVCR price forecast.
Analyzing the NVCR fundamentals
Trailing Twelve Months sales for NovoCure Ltd [NASDAQ:NVCR] were 621.71M which represents 11.91% growth. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -0.27%, Pretax Profit Margin comes in at -0.21%, and Net Profit Margin reading is -0.26%. To continue investigating profitability, this company’s Return on Assets is posted at -0.13, Equity is -0.45 and Total Capital is -0.33. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of1.92.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.72 points at the first support level, and at 15.43 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.49, and for the 2nd resistance point, it is at 16.97.
Ratios To Look Out For
To put it in perspective, the Current Ratio for NovoCure Ltd [NASDAQ:NVCR] is 1.47. Further, the Quick Ratio stands at 1.41, while the Cash Ratio is 0.17. Considering the valuation of this stock, the price to sales ratio is 2.87, the price to book ratio is 4.93.
Transactions by insiders
Recent insider trading involved Stafford Kristin, Director, that happened on Jun 03 ’25 when 999.0 shares were sold. Director, LEUNG GABRIEL completed a deal on Jun 03 ’25 to sell 999.0 shares. Meanwhile, Director Madden Martin J. sold 999.0 shares on Jun 03 ’25.
